DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2019 của Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals is developing DNA immune therapies to prevent and treat cancers and infectious diseases. Our SynCon immunotherapies delivered using our proprietary electroporation technology have generated best-in-class immune responses, with therapeutic T-cells exceeding other technologies. In a phase II cervical dysplasia study, our DNA immune therapy induced regression of precancerous cervical disease and cleared HPV infection. Roche exclusively licensed Inovio's DNA immunotherapies for prostate cancer and hepatitis B.

TÊN CÔNG TY / COMPANY
Inovio Pharmaceuticals, Inc.

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
INO

KỲ BÁO CÁO
2019

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare